Director Collier bought 4,000 RGLS shares at $1.82; holdings now 6,740 shares (+146.0%).
Director Kathryn J Collier purchased 4,000 shares of Regulus Therapeutics at $1.82 on 2024-07-25, increasing her stake by 146.0% from 2,740 to 6,740 shares. The transaction is notable for its scale relative to her prior holdings, though the absolute dollar value ($7,280.00) and company fundamentals warrant caution. Regulus reported zero revenue in its latest quarter, a net loss of $8,469,000.00, and negative annual revenue growth of -100.0%, indicating the company is in an unprofitable, early-stage or declining state. The current share price of $1.83 is 36.5% below the 52-week high of $2.88 and down 20.4% over the past 90 days, placing the purchase in a period of weakness. The transaction represents a meaningful accumulation by a board member at a depressed price level, but without additional context on company strategy or catalysts, it reflects positioning in a high-risk biotech entity with significant operational challenges.